Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B

Fardous F. El-Senduny, Farid A. Badria, Ahmed M. EL-Waseef, Subhash Chauhan, Fathi Halaweish

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Ovarian cancer is the most deadly gynecological cancer. The first line in treatment is platinum-based drugs. However, most patients suffer from tumor recurrence, characterized by resistance to cisplatin. A plausible approach to address the tumor resistance is to co-administer the chemotherapeutic agents along with natural products to offer a synergistic effect and optimize the dosage regimen. Cucurbitacin B is a natural product and displays antitumor activity against a wide array of cancer cell lines. The aim of this work is to determine the antitumor activity against ovarian cancer cell line (A2780) and possible sensitization activity on cisplatin-resistant cell line (A2780CP) in 2D and 3D culture model. 3D spheroids were generated from A2780CP cell line. A2780, A2780CP, and the spheroids were treated with cucurbitacin B, cisplatin alone, or pretreated with cucurbitacin B followed by cisplatin. The viability, cell cycle, and apoptosis were analyzed. Level of ROS and total glutathione was measured. In this study, cucurbitacin B showed cytotoxicity against the ovarian cancer cell lines, and pretreatment of A2780CP cells leads to a significant increase in the cytotoxicity of cisplatin. The mechanism behind the sensitization effect was dependent in part on the depletion of the total glutathione, an increase in ROS through a decrease in the level of dual-specificity tyrosine-regulated kinase (Dyrk1B), decrease in pERK1/2 and pSTAT3 level. The viability of spheroids treated with a combination of cisplatin and cucurbitacin B were significantly decreased. The resulting data shows that cucurbitacin B is a promising chemosensitizer for the cisplatin-resistant ovarian cancer.

Original languageEnglish (US)
Pages (from-to)685-698
Number of pages14
JournalTumor Biology
Volume37
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Ovarian Neoplasms
Cisplatin
Cell Line
Biological Products
Glutathione
Neoplasms
cucurbitacin B
Platinum
Protein-Tyrosine Kinases
Cell Cycle
Apoptosis
Recurrence
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. / El-Senduny, Fardous F.; Badria, Farid A.; EL-Waseef, Ahmed M.; Chauhan, Subhash; Halaweish, Fathi.

In: Tumor Biology, Vol. 37, No. 1, 01.01.2016, p. 685-698.

Research output: Contribution to journalArticle

El-Senduny, Fardous F. ; Badria, Farid A. ; EL-Waseef, Ahmed M. ; Chauhan, Subhash ; Halaweish, Fathi. / Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. In: Tumor Biology. 2016 ; Vol. 37, No. 1. pp. 685-698.
@article{2cfd96368a45470ca2b55f67a55701b7,
title = "Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B",
abstract = "Ovarian cancer is the most deadly gynecological cancer. The first line in treatment is platinum-based drugs. However, most patients suffer from tumor recurrence, characterized by resistance to cisplatin. A plausible approach to address the tumor resistance is to co-administer the chemotherapeutic agents along with natural products to offer a synergistic effect and optimize the dosage regimen. Cucurbitacin B is a natural product and displays antitumor activity against a wide array of cancer cell lines. The aim of this work is to determine the antitumor activity against ovarian cancer cell line (A2780) and possible sensitization activity on cisplatin-resistant cell line (A2780CP) in 2D and 3D culture model. 3D spheroids were generated from A2780CP cell line. A2780, A2780CP, and the spheroids were treated with cucurbitacin B, cisplatin alone, or pretreated with cucurbitacin B followed by cisplatin. The viability, cell cycle, and apoptosis were analyzed. Level of ROS and total glutathione was measured. In this study, cucurbitacin B showed cytotoxicity against the ovarian cancer cell lines, and pretreatment of A2780CP cells leads to a significant increase in the cytotoxicity of cisplatin. The mechanism behind the sensitization effect was dependent in part on the depletion of the total glutathione, an increase in ROS through a decrease in the level of dual-specificity tyrosine-regulated kinase (Dyrk1B), decrease in pERK1/2 and pSTAT3 level. The viability of spheroids treated with a combination of cisplatin and cucurbitacin B were significantly decreased. The resulting data shows that cucurbitacin B is a promising chemosensitizer for the cisplatin-resistant ovarian cancer.",
author = "El-Senduny, {Fardous F.} and Badria, {Farid A.} and EL-Waseef, {Ahmed M.} and Subhash Chauhan and Fathi Halaweish",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s13277-015-3773-8",
language = "English (US)",
volume = "37",
pages = "685--698",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B

AU - El-Senduny, Fardous F.

AU - Badria, Farid A.

AU - EL-Waseef, Ahmed M.

AU - Chauhan, Subhash

AU - Halaweish, Fathi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Ovarian cancer is the most deadly gynecological cancer. The first line in treatment is platinum-based drugs. However, most patients suffer from tumor recurrence, characterized by resistance to cisplatin. A plausible approach to address the tumor resistance is to co-administer the chemotherapeutic agents along with natural products to offer a synergistic effect and optimize the dosage regimen. Cucurbitacin B is a natural product and displays antitumor activity against a wide array of cancer cell lines. The aim of this work is to determine the antitumor activity against ovarian cancer cell line (A2780) and possible sensitization activity on cisplatin-resistant cell line (A2780CP) in 2D and 3D culture model. 3D spheroids were generated from A2780CP cell line. A2780, A2780CP, and the spheroids were treated with cucurbitacin B, cisplatin alone, or pretreated with cucurbitacin B followed by cisplatin. The viability, cell cycle, and apoptosis were analyzed. Level of ROS and total glutathione was measured. In this study, cucurbitacin B showed cytotoxicity against the ovarian cancer cell lines, and pretreatment of A2780CP cells leads to a significant increase in the cytotoxicity of cisplatin. The mechanism behind the sensitization effect was dependent in part on the depletion of the total glutathione, an increase in ROS through a decrease in the level of dual-specificity tyrosine-regulated kinase (Dyrk1B), decrease in pERK1/2 and pSTAT3 level. The viability of spheroids treated with a combination of cisplatin and cucurbitacin B were significantly decreased. The resulting data shows that cucurbitacin B is a promising chemosensitizer for the cisplatin-resistant ovarian cancer.

AB - Ovarian cancer is the most deadly gynecological cancer. The first line in treatment is platinum-based drugs. However, most patients suffer from tumor recurrence, characterized by resistance to cisplatin. A plausible approach to address the tumor resistance is to co-administer the chemotherapeutic agents along with natural products to offer a synergistic effect and optimize the dosage regimen. Cucurbitacin B is a natural product and displays antitumor activity against a wide array of cancer cell lines. The aim of this work is to determine the antitumor activity against ovarian cancer cell line (A2780) and possible sensitization activity on cisplatin-resistant cell line (A2780CP) in 2D and 3D culture model. 3D spheroids were generated from A2780CP cell line. A2780, A2780CP, and the spheroids were treated with cucurbitacin B, cisplatin alone, or pretreated with cucurbitacin B followed by cisplatin. The viability, cell cycle, and apoptosis were analyzed. Level of ROS and total glutathione was measured. In this study, cucurbitacin B showed cytotoxicity against the ovarian cancer cell lines, and pretreatment of A2780CP cells leads to a significant increase in the cytotoxicity of cisplatin. The mechanism behind the sensitization effect was dependent in part on the depletion of the total glutathione, an increase in ROS through a decrease in the level of dual-specificity tyrosine-regulated kinase (Dyrk1B), decrease in pERK1/2 and pSTAT3 level. The viability of spheroids treated with a combination of cisplatin and cucurbitacin B were significantly decreased. The resulting data shows that cucurbitacin B is a promising chemosensitizer for the cisplatin-resistant ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84938718918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938718918&partnerID=8YFLogxK

U2 - 10.1007/s13277-015-3773-8

DO - 10.1007/s13277-015-3773-8

M3 - Article

VL - 37

SP - 685

EP - 698

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 1

ER -